Strategic Advocates’s Boston Scientific BSX Stock Holding History

Strategic Advocates’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$130K	Sell	2,073 -25,392	-92%	-$2.03M	0.58%	40
2025 Q4	$2.64M	Buy	27,465 +3,358	+14%	+$329K	0.67%	24
2025 Q3	$2.35M	Buy	24,107 +2,697	+13%	+$279K	0.61%	28
2025 Q2	$2.3M	Buy	21,410 +1,517	+8%	+$153K	0.68%	26
2025 Q1	$2.01M	Buy	+19,893	New	+$2M	0.7%	26

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Strategic Advocates's BSX Position: Q1 2026 in Review

Strategic Advocates reduced its Boston Scientific (BSX) stake by 92% in Q1 2026, selling an estimated $2.03M and leaving 2,073 shares worth $130K. The position accounts for 0.58% of the portfolio, ranked #40.

Strategic Advocates first reported a position in BSX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.64M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Strategic Advocates held 2,073 shares of Boston Scientific worth $130K as of Q1 2026.
Strategic Advocates sold 25,392 Boston Scientific shares in Q1 2026, an estimated $2.03M.
Boston Scientific made up 0.58% of Strategic Advocates's portfolio in Q1 2026, its #40 holding.
Strategic Advocates first reported a position in Boston Scientific in Q1 2025 and has held it in 5 quarters since.
Strategic Advocates's Boston Scientific position peaked at $2.64M in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.